Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | PLEC | Q15149 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 6/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10145603 | 0.92 | KDM4E (0.46) | KDM4EPKMGAAMAPTTP53 | |
| SCHEMBL15298593 | 0.91 | KDM4E (0.47) | KDM4EPKMGAAMAPTTP53 | |
| SCHEMBL10122171 | 0.82 | KAT6A (0.57) | KDM4EPKMGAAMAPTTP53 | |
| SCHEMBL10122155 | 0.81 | KAT6A (0.54) | KDM4EPKMGAAMAPTTP53 | |
| SCHEMBL10122206 | 0.81 | KDM4E (0.47) | KDM4EPKMGAAMAPTTP53 | |
| SCHEMBL10122217 | 0.80 | KDM4E (0.46) | KDM4EPKMGAAMAPTTP53 | |
| SCHEMBL10122111 | 0.78 | CA1 (0.45) | KDM4EPKMGAAMAPTTP53 | |
| SCHEMBL10122165 | 0.75 | KAT6A (0.54) | GAAKAT6ALMNAKMT2A | |
| SCHEMBL10122183 | 0.75 | BCAT1 (0.55) | KDM4EPKMGAAMAPTTP53 | |
| SCHEMBL10122160 | 0.74 | KAT6A (0.55) | GAAKAT6AHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115065-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses | Kineta, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9067873-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | Kineta Four, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8664274-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses | SIGA TECHNOLOGIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8658697-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130261087-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES | SIGA TECHNOLOGIES INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8410149-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120022027-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110118505-A1 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118505-A1 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SORD, GBA1, GK | KDM4E 1039/4885PKM 702/4885GAA 32/4885 |
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | KDM4E 1778/4885PKM 757/4885GAA 40/4885 |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | KDM4E 1778/4885PKM 757/4885GAA 40/4885 |
| US-20130261087-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES | SORD, GBA1, GK | KDM4E 957/4885PKM 731/4885GAA 34/4885 |
| US-20120022027-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | KDM4E 1778/4885PKM 757/4885GAA 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.